Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Driving Neuronal Differentiation through Reversal of an ERK1/2-miR-124-SOX9 Axis Abrogates Glioblastoma Aggressiveness.

Sabelström H, Petri R, Shchors K, Jandial R, Schmidt C, Sacheva R, Masic S, Yuan E, Fenster T, Martinez M, Saxena S, Nicolaides TP, Ilkhanizadeh S, Berger MS, Snyder EY, Weiss WA, Jakobsson J, Persson AI.

Cell Rep. 2019 Aug 20;28(8):2064-2079.e11. doi: 10.1016/j.celrep.2019.07.071.

2.

Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.

McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, Nicolaides TP, Yong WH, Lai A, Hegi ME, Weiss WA, Phillips JJ.

Mol Cancer Ther. 2019 Sep;18(9):1565-1576. doi: 10.1158/1535-7163.MCT-18-1330. Epub 2019 Jul 3.

PMID:
31270152
3.

Evaluation of Three Morphologically Distinct Virus-Like Particles as Nanocarriers for Convection-Enhanced Drug Delivery to Glioblastoma.

Finbloom JA, Aanei IL, Bernard JM, Klass SH, Elledge SK, Han K, Ozawa T, Nicolaides TP, Berger MS, Francis MB.

Nanomaterials (Basel). 2018 Dec 5;8(12). pii: E1007. doi: 10.3390/nano8121007.

4.

Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.

Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara CM, Frenster JD, Tateishi K, Wakimoto H, Jain R, Riina HA, Nicolaides TP, Sulman EP, Cahill DP, Golfinos JG, Isse K, Saunders LR, Zagzag D, Placantonakis DG, Snuderl M, Chi AS.

Clin Cancer Res. 2019 Feb 15;25(4):1261-1271. doi: 10.1158/1078-0432.CCR-18-2312. Epub 2018 Nov 5.

PMID:
30397180
5.

Inhibiting 4EBP1 in Glioblastoma.

Fan QW, Nicolaides TP, Weiss WA.

Clin Cancer Res. 2018 Jan 1;24(1):14-21. doi: 10.1158/1078-0432.CCR-17-0042. Epub 2017 Jul 10. Review.

6.

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.

Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK.

Oncotarget. 2016 Nov 15;7(46):75839-75853. doi: 10.18632/oncotarget.12419.

7.

Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):395. doi: 10.1007/s11060-015-2024-6. No abstract available.

PMID:
26782702
8.

Targeted Therapy for MAPK Alterations in Pediatric Gliomas.

Truong AY, Nicolaides TP.

Brain Disord Ther. 2015 Aug;Suppl 2. pii: 005. Epub 2015 Jul 18.

9.

Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.

Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA.

J Neurooncol. 2016 Feb;126(3):385-93. doi: 10.1007/s11060-015-1939-2. Epub 2015 Sep 18. Erratum in: J Neurooncol. 2016 Feb;126(3):395.

10.

Targeted therapy for BRAFV600E malignant astrocytoma.

Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, Waldman TA, James CD.

Clin Cancer Res. 2011 Dec 15;17(24):7595-604. doi: 10.1158/1078-0432.CCR-11-1456. Epub 2011 Oct 28.

11.

Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.

Yoon DJ, Kwan BH, Chao FC, Nicolaides TP, Phillips JJ, Lam GY, Mason AB, Weiss WA, Kamei DT.

Cancer Res. 2010 Jun 1;70(11):4520-7. doi: 10.1158/0008-5472.CAN-09-4311. Epub 2010 May 11.

12.

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.

Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA.

Cancer Res. 2007 Sep 1;67(17):7960-5.

13.

High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors.

Broniscer A, Nicolaides TP, Dunkel IJ, Gardner SL, Johnson J Jr, Allen JC, Sposto R, Finlay JL.

Pediatr Blood Cancer. 2004 Mar;42(3):261-7.

PMID:
14752864

Supplemental Content

Loading ...
Support Center